Genesis Biomed

Genesis Biomed focuses on early-stage investments, including seed, start-up, and spin-off opportunities. The firm is structured to enter at the point where academic research becomes a commercial venture, providing both capital and company-building support. This narrow stage focus means it does not compete for later-stage growth equity or buyout deals in the life-sciences sector.

The firm's mandate spans biomedical and health-tech ventures broadly, including digital health, medical devices, diagnostics, and therapeutic platforms. Genesis Biomed evaluates opportunities that originate from academic research institutions and require specialized scientific vetting. It does not publicly state any sub-sector exclusions, but its deal flow is naturally shaped by the research strengths of its Southern European network.

Genesis Biomed sources opportunities primarily through its network of research institutions, universities, and teaching hospitals in Spain and across Europe. The firm's Barcelona headquarters places it in a dense biomedical research cluster, giving it proximity to academic spin-offs before they reach broader venture auction processes. This relationship-driven origination model is common among specialized early-stage health-tech funds in Europe.

Genesis Biomed is structured as a private equity and venture capital firm, not a single family office. It operates as an asset manager raising external capital to deploy into biomedical ventures. Public records do not indicate any affiliation with a single-family wealth source or a multi-family office structure.

Genesis Biomed invests primarily in Spain and the broader European market. Its Barcelona headquarters anchors it in one of Southern Europe's most active biomedical research ecosystems, and the firm's deal flow reflects that regional concentration. It has not publicly disclosed any dedicated offices or investment programs outside of Europe.